Recent studies have determined an optimal therapy dose and shown the exquisite potential effectiveness of 177Lu labeled trastuzumab for treatment of disseminated, HER2 positive, peritoneal disease [10]. This evidence concerns the gene ERBB2 and disease of peritoneum.